Quincy Bioscience Makes Inc. 500 List of America's Fastest Growing Companies

Madison, Wis -- (August 20, 2012) In the first year of eligibility, Quincy Bioscience has been included in the Inc. 500 list of fastest growing private companies in the United States, and has been ranked at #398.  Quincy Bioscience, based in Madison, WI, is a biotechnology company committed to improving cognitive health in the aging population. 

In 2007, Quincy Bioscience introduced the brain health supplement Prevagen® for clearer thinking.  Prevagen contains the patented compound apoaequorin – a first-in-class technology which has proven effective at improving brain cell survival and increasing domains of cognitive function such as executive function, short-term memory, and word recall.

Quincy Bioscience would like to thank staff, clinical trial participants, and the many supporters that have made the incredible growth of the company possible.

“The privilege of being ranked in the Inc. 500 list is a testament to the value of apoaequorin research for preventative neurological care,” says Quincy Bioscience President Mark Underwood. “Apoaequorin has proven that it is capable of changing the lives of millions of Americans. We are honored to continue working towards the goal of better and healthier brains for people worldwide.”

In 1982, Inc. introduced the Inc. 500 list of the fastest-growing privately held companies in the United States.  Today, the list is a distinguished editorial award, a celebration of innovation, and a network of entrepreneurial leaders. The Inc. 500|5000 ranks companies by overall revenue growth over a three-year period.

To learn more about the valuable apoaequorin research by Quincy Bioscience, please visit the website.

About Quincy Bioscience

Quincy Bioscience is a biotechnology company based in Madison, Wisconsin focused on the discovery and development of novel compounds to improve cognitive performance and therapeutics to treat age related memory loss and diseases of aging. The company’s technology focuses on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms.

Media Contact:
Todd Olson
(608) 827-8134
tolson@quincybioscience.com

Tags: